dietworks glp-1 companion semaglutide support Weight Loss Program, Recipes & Help Ozempic, Wegovy inspire wave of

GLP-1 patient volume exhibited consistent and substantial growth throughout the observation period, with an initial 37.9% increase in 2019, ultimately reaching a 744.6% increase by 2023 relative to the 2018 baseline (Figure 1)

Clinical Evidence Semaglutide: proof of concept for high-efficacy GLP-1 therapy Semaglutide 2.4 mg established that selective GLP-1 receptor agonism could produce substantial weight loss in adults with obesity

Anyone taking semaglutide who is pregnant, plans to become pregnant, or may become pregnant should discuss their situation with a healthcare provider immediately

While Wegovy is approved by the Therapeutic Goods Administration for use in the management of obesity, its not yet available in Australia due to global shortages of semaglutide